EIF4EBP1 and neoplasm: Combined inhibition of AKT and mTORC1 is required for effective inhibition of PRAS40 phosphorylation on both Ser183 and Thr246 sites, which in turn increases the ability of PRAS40 to inhibit mTORC1-mediated 4E-BP1 phosphorylation and translation concomitant with suppression of tumor growth and cell motility.